JP2010502674A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010502674A5 JP2010502674A5 JP2009527140A JP2009527140A JP2010502674A5 JP 2010502674 A5 JP2010502674 A5 JP 2010502674A5 JP 2009527140 A JP2009527140 A JP 2009527140A JP 2009527140 A JP2009527140 A JP 2009527140A JP 2010502674 A5 JP2010502674 A5 JP 2010502674A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- chloro
- cycloalkyl
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- YJVKLLJCUMQBHN-UHFFFAOYSA-N 2-pyridin-2-ylpyrimidine Chemical class N1=CC=CC=C1C1=NC=CC=N1 YJVKLLJCUMQBHN-UHFFFAOYSA-N 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 102000004257 Potassium Channel Human genes 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 108020001213 potassium channel Proteins 0.000 claims 4
- 206010010904 Convulsion Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 208000023504 respiratory system disease Diseases 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 206010046543 Urinary incontinence Diseases 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- -1 cyano, nitro, amino, phenyl Chemical group 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 201000001881 impotence Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- DEHXYZLLVRLTQT-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(6-chloropyridin-2-yl)-6-methylpyrimidin-4-amine Chemical compound N=1C(C=2N=C(Cl)C=CC=2)=NC(C)=CC=1NC1=CC=C(Cl)C=C1 DEHXYZLLVRLTQT-UHFFFAOYSA-N 0.000 claims 2
- VBSJJTJCXKEDDH-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(6-chloropyridin-2-yl)pyrimidin-4-amine Chemical compound C1=CC(Cl)=CC=C1NC1=CC=NC(C=2N=C(Cl)C=CC=2)=N1 VBSJJTJCXKEDDH-UHFFFAOYSA-N 0.000 claims 2
- OFQLLYAMPFKHRN-UHFFFAOYSA-N n-(4-chlorophenyl)-6-methyl-2-pyridin-2-ylpyrimidin-4-amine Chemical compound N=1C(C=2N=CC=CC=2)=NC(C)=CC=1NC1=CC=C(Cl)C=C1 OFQLLYAMPFKHRN-UHFFFAOYSA-N 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- VFRVPSXUIPASJT-UHFFFAOYSA-N 4-methyl-6-(4-methylphenyl)sulfanyl-2-pyridin-2-ylpyrimidine Chemical group C1=CC(C)=CC=C1SC1=CC(C)=NC(C=2N=CC=CC=2)=N1 VFRVPSXUIPASJT-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010003225 Arteriospasm coronary Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 206010048994 Bladder spasm Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 claims 1
- 206010036600 Premature labour Diseases 0.000 claims 1
- 208000003782 Raynaud disease Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 208000036071 Rhinorrhea Diseases 0.000 claims 1
- 206010039101 Rhinorrhoea Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 208000028938 Urination disease Diseases 0.000 claims 1
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 208000005946 Xerostomia Diseases 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013781 dry mouth Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 230000008629 immune suppression Effects 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- NWIRUHKMLLCBHB-UHFFFAOYSA-N n-(4-chlorophenyl)-2-pyridin-2-ylpyrimidin-4-amine Chemical compound C1=CC(Cl)=CC=C1NC1=CC=NC(C=2N=CC=CC=2)=N1 NWIRUHKMLLCBHB-UHFFFAOYSA-N 0.000 claims 1
- NOJFPSSMYWQWHX-UHFFFAOYSA-N n-(4-chlorophenyl)-6-methyl-2-(6-methylpyridin-2-yl)pyrimidin-4-amine Chemical compound CC1=CC=CC(C=2N=C(NC=3C=CC(Cl)=CC=3)C=C(C)N=2)=N1 NOJFPSSMYWQWHX-UHFFFAOYSA-N 0.000 claims 1
- CHACNMTZSNLFAT-UHFFFAOYSA-N n-phenyl-2-pyridin-2-yl-6-(trifluoromethyl)pyrimidin-4-amine Chemical compound N=1C(C=2N=CC=CC=2)=NC(C(F)(F)F)=CC=1NC1=CC=CC=C1 CHACNMTZSNLFAT-UHFFFAOYSA-N 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 208000026440 premature labor Diseases 0.000 claims 1
- 230000008085 renal dysfunction Effects 0.000 claims 1
- 201000009881 secretory diarrhea Diseases 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82481606P | 2006-09-07 | 2006-09-07 | |
| DKPA200601151 | 2006-09-07 | ||
| PCT/EP2007/059313 WO2008028935A2 (en) | 2006-09-07 | 2007-09-06 | Pyridinyl-pyrimidine derivatives useful as potassium channel modulating agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010502674A JP2010502674A (ja) | 2010-01-28 |
| JP2010502674A5 true JP2010502674A5 (enExample) | 2010-10-21 |
Family
ID=44143641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009527140A Abandoned JP2010502674A (ja) | 2006-09-07 | 2007-09-06 | カリウムチャンネル調節剤として有用なピリジニル−ピリミジン誘導体 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20110144140A1 (enExample) |
| EP (1) | EP2066655A2 (enExample) |
| JP (1) | JP2010502674A (enExample) |
| WO (1) | WO2008028935A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2114916A2 (en) * | 2007-02-02 | 2009-11-11 | NeuroSearch A/S | Pyridinyl-pyrazole derivatives and their use as potassium channel modulators |
| EP2142546B1 (en) | 2007-03-28 | 2017-06-07 | Saniona A/S | Purinyl derivatives and their use as potassium channel modulators |
| EP2885290B1 (en) | 2012-06-26 | 2017-10-18 | Saniona A/S | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| WO2017112777A1 (en) * | 2015-12-22 | 2017-06-29 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| WO2017210545A1 (en) | 2016-06-02 | 2017-12-07 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| EP3571193B1 (en) | 2017-01-23 | 2021-12-01 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| KR102736865B1 (ko) | 2017-06-21 | 2024-12-03 | 샤이 테라퓨틱스 엘엘씨 | 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물 |
| MX2021004647A (es) | 2018-10-22 | 2021-08-16 | Novartis Ag | Formas cristalinas de moduladores de los canales de potasio. |
| JP7407461B2 (ja) | 2018-12-19 | 2024-01-04 | シャイ・セラピューティクス・エルエルシー | がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3922735A1 (de) * | 1989-07-11 | 1991-01-24 | Hoechst Ag | Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide |
| DE4029649A1 (de) * | 1990-09-19 | 1992-03-26 | Hoechst Ag | Alkoxypyridyl-pyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide |
| JP2001089452A (ja) * | 1999-09-22 | 2001-04-03 | Sankyo Co Ltd | ピリミジン誘導体 |
| EP1351691A4 (en) * | 2000-12-12 | 2005-06-22 | Cytovia Inc | SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF |
| EP1254903B1 (en) * | 2001-04-20 | 2005-06-08 | Ciba SC Holding AG | 4-Amino-2-(pyridin-2-yl)pyrimidine as microbicidal active substances |
| TW200637556A (en) * | 2005-01-31 | 2006-11-01 | Basf Ag | Substituted 5-phenyl pyrimidines I in therapy |
| NZ556248A (en) * | 2005-03-14 | 2010-06-25 | Neurosearch As | Pyrazolyl-quinazoline potassium channel modulating agents and their medical use |
| US20090036475A1 (en) * | 2005-03-22 | 2009-02-05 | Neurosearch A/S | Pyrazolyl-Pyrimidines as Potassium Channel Modulating Agents and Their Medical Use |
| WO2007071632A2 (en) * | 2005-12-20 | 2007-06-28 | Neurosearch A/S | 2-pyridin-2-yl-quinazoline derivatives as potassium channel modulating agents for the treatment of respiratory diseases |
| JP2010505794A (ja) * | 2006-10-03 | 2010-02-25 | ノイロサーチ アクティーゼルスカブ | カリウムチャネル調節剤として有用なインダゾリル誘導体 |
-
2007
- 2007-09-06 US US12/377,392 patent/US20110144140A1/en not_active Abandoned
- 2007-09-06 WO PCT/EP2007/059313 patent/WO2008028935A2/en not_active Ceased
- 2007-09-06 JP JP2009527140A patent/JP2010502674A/ja not_active Abandoned
- 2007-09-06 EP EP07803273A patent/EP2066655A2/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009519995A5 (enExample) | ||
| JP2010505794A5 (enExample) | ||
| JP2010522718A5 (enExample) | ||
| AU2010339423C1 (en) | Therapeutic compounds and related methods of use | |
| JP2008534472A5 (enExample) | ||
| JP6522682B2 (ja) | 治療用化合物、及び関連する使用の方法 | |
| US9174946B2 (en) | Selective FAK inhibitors | |
| JP2018534326A5 (enExample) | ||
| JP6043935B2 (ja) | ピペラジノトリアゾール化合物及びその製造方法と製薬用途 | |
| JP2014522837A (ja) | 治療用化合物としてのキナゾリン及び関連の使用方法 | |
| JP2008533087A5 (enExample) | ||
| MX2009003142A (es) | Derivados de indazolilo utiles como agentes moduladores del canal de potasio. | |
| JP2020506899A5 (enExample) | ||
| JP2012530129A5 (enExample) | ||
| JP2020506895A (ja) | インドールアミン２，３−ジオキシゲナーゼおよび／またはトリプトファンジオキシゲナーゼの阻害剤として有用な化合物 | |
| JP2008543860A5 (enExample) | ||
| WO2012075917A1 (en) | Compounds | |
| JP2011510991A5 (enExample) | ||
| JP7465266B2 (ja) | 細菌感染症の治療と予防のための三環式化合物 | |
| JP2010509249A5 (enExample) | ||
| JP2009511548A5 (enExample) | ||
| AU2012275326A1 (en) | Quinazolines as therapeutic compounds and related methods of use | |
| HK1173654B (en) | Therapeutic compounds and related methods of use |